Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)
Trial · NCT04655313
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Plasma Concentration of ARQ-151 Cream 0.3% | ARQ-151 Cream 0.3% | Day 14 | 3.15 | Standard Deviation 3.64 | ng/mL |
| Plasma Concentration of ARQ-151 Cream 0.3% | ARQ-151 Cream 0.3% | Day 28 | 1.68 | Standard Deviation 1.57 | ng/mL |
| Plasma Concentration of the Roflumilast Major N-oxide Metabolite | ARQ-151 Cream 0.3% | Day 14 | 28.9 | Standard Deviation 41.1 | ng/mL |
| Plasma Concentration of the Roflumilast Major N-oxide Metabolite | ARQ-151 Cream 0.3% | Day 28 | 15.7 | Standard Deviation 15.8 | ng/mL |
| Number of Participants With ≥1 Adverse Event (AE) | ARQ-151 Cream 0.3% | 4 | Participants | ||
| Number of Participants With Application Site Reactions | ARQ-151 Cream 0.3% | Day 1: No erythema | 18 | Participants | |
| Number of Participants With Application Site Reactions | ARQ-151 Cream 0.3% | Day 1: Minimal erythema | 0 | Participants | |
| Number of Participants With Application Site Reactions | ARQ-151 Cream 0.3% | Day 1: Definite erythema | 1 | Participants | |
| Number of Participants With Application Site Reactions | ARQ-151 Cream 0.3% | Day 7: No erythema | 17 | Participants | |
| Number of Participants With Application Site Reactions | ARQ-151 Cream 0.3% | Day 7: Minimal erythema | 3 | Participants | |
| Number of Participants With Application Site Reactions | ARQ-151 Cream 0.3% | Day 7: Definite erythema | 0 | Participants | |
| Number of Participants With Application Site Reactions | ARQ-151 Cream 0.3% | Day 14: No erythema | 19 | Participants | |
| Number of Participants With Application Site Reactions | ARQ-151 Cream 0.3% | Day 14: Minimal erythema | 1 | Participants | |
| Number of Participants With Application Site Reactions | ARQ-151 Cream 0.3% | Day 14: Definite erythema | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04655313/results